Pyridine-2-amine derivative and pharmaceutical composition and use thereof
US-2024116962-A1 · Apr 11, 2024 · US
Herpes simplex virus type-1(HSV-1) vaccine strain VC2 generating an anti-EHV-1 immune response
US10328147B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10328147-B2 |
| Application number | US-201815928377-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 22, 2018 |
| Priority date | Mar 24, 2017 |
| Publication date | Jun 25, 2019 |
| Grant date | Jun 25, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Embodiments of nucleic acids comprise a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. Also provided is a live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter.
First claim
Opening claim text (preview).
I claim: 1. A recombinant nucleic acid comprising a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, wherein the nucleotide sequence encoding the heterologous polypeptide operably linked to a promoter encodes the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. 2. A live-attenuated recombinant Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, wherein the nucleotide sequence encoding the heteroloqous polypeptide operably linked to a promoter encodes the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. 3. A viral vaccine comprising a physiologically acceptable carrier and an immunogenic amount of a chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus comprising a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, wherein the nucleotide sequence encoding the heteroloqous polypeptide operably linked to a promoter encodes the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. 4. The viral vaccine of claim 3 wherein the physiologically acceptable carrier comprises an adjuvant. 5. A method of generating an antibody in an animal, wherein said method comprises the step of administering to an animal a pharmaceutically acceptable composition comprising a chimeric live-attenuated Herpes Simplex Virus Type-1 (HSV-1) VC2 virus, said virus comprising a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, and a physiologically acceptable carrier, wherein the nucleotide sequence encoding the heterologous polypeptide operably linked to a promoter encodes the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof. 6. A method of generating an immune response in an animal, wherein said method comprising the step of administering to an animal a pharmaceutically acceptable composition comprising a chimeric live-attenuated Herpes Simplex Virus Type-1 (HSV-1) VC2 virus, said virus comprising a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter, and a physiologically acceptable carrier, wherein the nucleotide sequence encoding the heterologous polypeptide operably linked to a promoter encodes the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1) or a fragment thereof.
Assignees
Inventors
Classifications
- A61P31/22Primary
for herpes viruses · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Herpes simplex virus · CPC title
Viral antigens · CPC title
viral genome or elements thereof as genetic vector · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10328147B2 cover?
- Embodiments of nucleic acids comprise a nucleotide sequence encoding a live-attenuated chimeric Herpes Simplex Virus Type-1 (HSV-1) VC2 virus and a nucleotide sequence encoding a heterologous polypeptide operably linked to a promoter. The nucleotide sequence encoding the heterologous polypeptide can be operably linked to a promoter encoding the glycoprotein D (gD) of Equine Herpesvirus-1 (EHV-1…
- Who is the assignee on this patent?
- Univ Louisiana State
- What technology area does this patent fall under?
- Primary CPC classification A61P31/22. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).